Grant Private Wealth Management Inc Purchases Shares of 14,518 10x Genomics, Inc. (NASDAQ:TXG)

Grant Private Wealth Management Inc acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,518 shares of the company’s stock, valued at approximately $209,000.

Other large investors have also made changes to their positions in the company. Bryce Point Capital LLC bought a new position in 10x Genomics during the fourth quarter valued at about $448,000. Trexquant Investment LP increased its position in shares of 10x Genomics by 196.2% during the fourth quarter. Trexquant Investment LP now owns 594,611 shares of the company’s stock valued at $8,539,000 after purchasing an additional 393,854 shares during the period. National Bank of Canada FI acquired a new position in shares of 10x Genomics in the fourth quarter valued at $1,518,000. Norges Bank bought a new position in 10x Genomics in the fourth quarter worth $1,315,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in 10x Genomics by 160.9% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 52,787 shares of the company’s stock worth $758,000 after buying an additional 32,555 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $8.85 on Thursday. 10x Genomics, Inc. has a fifty-two week low of $8.42 and a fifty-two week high of $37.74. The firm has a market capitalization of $1.08 billion, a P/E ratio of -5.82 and a beta of 1.93. The company’s 50 day simple moving average is $11.70 and its 200 day simple moving average is $14.80.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Sell-side analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Stifel Nicolaus dropped their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. UBS Group dropped their price target on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. JPMorgan Chase & Co. decreased their price objective on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, March 22nd. Finally, Leerink Partnrs downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $20.21.

Insider Activity at 10x Genomics

In other news, Director Alan Mateo purchased 40,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The stock was bought at an average price of $11.14 per share, with a total value of $445,600.00. Following the acquisition, the director now directly owns 61,691 shares of the company’s stock, valued at approximately $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Serge Saxonov sold 5,092 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the sale, the chief executive officer now directly owns 879,482 shares in the company, valued at $9,735,865.74. The trade was a 0.58 % decrease in their position. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by corporate insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.